Licensing for Tamiflu may begin
Indian generic firms might finally be able to manufacture Tamiflu. In a statement, Roche AG, the Swiss pharmaceutical giant that holds patent for the drug, said that it is ready to issue emergency licenses of the drug to generic companies across the world. Under WTO TRIPS Agreement, emergency license allows a non-patent holder pharma company to manufacture patented drugs in case of an emergency declared by the government.
Roche has agreed to meet with four generic drug companies including Ranbaxy Laboratories to discuss allowing them to manufacture the anti-influenza drug Tamiflu (Oseltamivir), which is in short supply, as countries stockpile it to prepare for a possible flu pandemic.
Besides Ranbaxy, Roche said it’s ready to talk to Teva Pharmaceutical Industries, Barr Pharmaceuticals and Mylan Laboratories. As fears of the pandemic mount, generic companies wanted to start production to meet the drug’s surging demand. Cipla, which had first expressed desire to manufacture the drug’s generic version, does not figure in Roche’s plans.
Express News Service